Skip to main content

bupropion

Generic: Bupropion·Brand: Aplenzin, Auvelity, BUPROPION HYDROCHLORIDE, Contrave, FORFIVO XL, Forfivo, WELLBUTRIN, WELLBUTRIN SR, WELLBUTRIN XL, Wellbutrin, ZYBAN

bupropion: 9 clinical trials tracked.

bupropion evidence translation

What we can confirm

9 tracked trials

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about bupropion, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence6 indications · 3 study sponsors
Clinical Trial Registry Records (9)

Abstinence Reinforcement Therapy for Veterans Who Smoke Tobacco and Are Experiencing Homelessness

NCT07714200Registry updated 2026-07-20·N/A
Not yet recruiting

Primary endpoint: Number of participants whose self-report of prolonged smoking abstinence is bioverified

InterventionalRandomizedopen120 targetStarted 2027-03Completion 2030-091 site · United StatesVA Office of Research and Development

A Randomized, Double-Blind, Placebo and Active-Controlled Trial to Evaluate the Efficacy and Safety of AXS-05 for Smoking Cessation in Adults

NCT07766655Registry updated 2026-09-08·Phase 3·AXSM
Recruiting

Primary endpoint: 4-Week Continuous Smoking Abstinence Rate

InterventionalRandomizeddouble705 targetStarted 2026-08Completion 2027-1216 sites · United StatesAxsome Therapeutics, Inc.

A Phase 1, First-in-human Study Evaluating the Safety, Tolerability, and Pharmacokinetics of VX-433 and Its Effects on the Pharmacokinetics of Midazolam and Bupropion

NCT07584434Registry updated 2026-06-08·Phase 1
Recruiting

Primary endpoint: Part A: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

InterventionalRandomizedquadruple118 targetStarted 2026-05Completion 2027-031 site · United StatesVertex Pharmaceuticals Incorporated

Phase 1, 2-Cohort, Open-label, Fixed-sequence, Drug-drug Interaction Study to Evaluate the Effect of Repotrectinib on the Pharmacokinetics of Transporter and CYP P450 Probe Substrates in Healthy Adult Participants

NCT07223671Registry updated 2026-03-27·Phase 1·BMY
Completed

Primary endpoint: Cohort 1: Area Under the Plasma Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration of AUC (0-T) of Probe Substrate With Repotrectinib

Interventionalopen30 enrolledStarted 2025-12Completion 2026-031 site · United StatesBristol-Myers Squibb

Effectiveness of Semaglutide 2.4 mg vs. Commercially Available Medications for Chronic Weight Management in Participants With Obesity in a Multi-employer Setting in The US - a Pragmatic Clinical Study

NCT05579249Registry updated 2026-01-14·Phase 4·NVO
Completed

Primary endpoint: Number of Participants Who Achieved Greater Than or Equal to (≥) 10.0 Percent (%) Body Weight Reduction (Yes/no)

InterventionalRandomizedopen500 enrolledStarted 2023-01Completion 2024-111 site · United StatesNovo Nordisk A/S

A Randomized Controlled Trial to Determine the Effects of Combination Zonisamide and Bupropion on Switching to an Electronic Cigarette

NCT05205811Registry updated 2026-02-06·Phase 3
Completed

Primary endpoint: Complete Switching From Combustible Cigarettes to JUUL e-cigarette as measured by Exhaled carbon monoxide (CO)

InterventionalRandomizeddouble180 enrolledStarted 2021-12Completion 2025-102 sites · United StatesRose Research Center, LLC

CPT-SMART for Treatment of PTSD and Cigarette Smoking

NCT03978442Registry updated 2026-07-02·Phase 4
Completed

Primary endpoint: Number of Participants Whose Self-report of 7 Day Point Prevalence Abstinence From Smoking is Bioverified

InterventionalRandomizedopen115 enrolledStarted 2019-11Completion 2025-101 site · United StatesVA Office of Research and Development

Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants

NCT03511118Registry updated 2026-02-11·N/A
Recruiting

Primary endpoint: M/P ratio

Observational1,600 targetStarted 2018-10Completion 2027-0722 sites · Canada, United StatesDuke University

Phase II Double Blind Dose Finding Trial of Bupropion Versus Placebo for Sexual Desire in Women With Breast or Gynecologic Cancer

NCT03180294Registry updated 2026-07-10·Phase 2
Completed

Primary endpoint: Change From Baseline at 9 Weeks in the Desire Subscore of the Female Sexual Function Index ("Sexual Desire")

InterventionalRandomizeddouble230 enrolledStarted 2017-05Completion 2021-0250 sites · United StatesNRG Oncology